Transcatheter-implanted aortic valve device

Abstract

The invention discloses a transcatheter-implanted aortic valve device, comprising: a valve stent; valve leaflets fixed in the valve support; an inner skirt and an outer skirt are peripherally fixed to the inner and outer sides of the valve support; the inflow end of the valve support is of lower flared structure composed of a plurality of diamond structures; three connection claws required to load the valve stent are arranged at the tail end of the lower flared structure; a plurality of positioning structures extended up and out are arranged in the middle of the valve support, close to the outer side of an inflow end portion; a plurality of pored straight rod connection structures are arranged in the middle of the valve stent close to the outflow end portion; the positioning structures for the valve stent are used for limiting a position at the aortic valve ring where the valve stent is replaced in; the outflow end of the valve stent is of upper flared structure composed of a plurality of large-mesh diamond structures; the large-mesh diamond structures are distributed evenly so that the valve support is kept coaxial and stable to a vessel in the ascending aorta.

Description

technical field [0001] Embodiments of the present invention relate to the field of medical devices, in particular to a transcatheter implanted aortic valve device for a mammalian heart. Background technique [0002] With the prolongation of life expectancy and the process of population aging, the number of patients with aortic valve diseases, including aortic stenosis (AS) and aortic regurgitation / regurgitation (AR), will further increase . Aortic valve disease is the most common type of valvular heart disease. Especially in the elderly population, the incidence of aortic valve stenosis is on the rise. In Europe and the United States, the incidence rate among the population over 65 years old is 2% to 7%, and it gradually increases with age. The population reaches 4.6% to 13%. Initially, aortic valve disease can only be treated conservatively with drugs, but the prognosis of conservative medical treatment is poor, and the 5-year mortality rate can be as high as 52% to 82%....

AI Technical Summary

Problems solved by technology

[0004] At present, the existing transcatheter implantable aortic valve devices on the market mainly include the Sapien valve family of Edwards Lifesciences and the CoreValve valve family of Medtronic, etc., but they have more or less deficiencies during use, or cannot be recycled. Either it is not easy to position, or it cannot be adapted to both patients with aortic valve stenosis and patients with aortic valve insufficiency

Images